UroGen Pharma is a biotechnology company focused on developing and commercializing innovative treatments for urological cancers and specialty urologic conditions. The company is headquartered in Princeton, New Jersey, and was founded in 2004. UroGen’s lead commercial product is JELMYTO, a reverse thermal gel formulation approved for the treatment of low-grade upper tract urothelial cancer, and its pipeline includes additional therapies for bladder and other urothelial cancers. The company operates in the United States and Israel. UroGen reported revenue of approximately $82 million in 2023. It employs roughly 200 people.
Verified Email Pattern
{first}.{last}@urogen.com
b****@urogen.com
d****@urogen.com
Find a verified email at UroGen Pharma
Look up any prospect by name, or by name and company, across 110M contacts.
Employees Directory
Showing 6 of 6 employees with verified contact records
| Name | Location | Verified Email |
|---|---|---|
|
Bhagya Joseph
Pharmaceutical Professional
|
|
b****@urogen.com
|
|
Diana Yankovitch
Director of Intellectual Property
|
|
d****@urogen.com
|
|
Fazela Brasse
Pharmaceutical Professional
|
|
f****@urogen.com
|
|
Hasib Zabih
Pharmaceutical Professional
|
|
h****@urogen.com
|
|
Sophia Batista
Pharmaceutical Professional
|
|
s****@urogen.com
|
|
Timothy Simon
Pharmaceutical Professional
|
|
t****@urogen.com
|
Protected by reCAPTCHA. Google Privacy Policy and Terms of Service apply.